Today, the International Myeloma Foundation (IMF) announced the launch of the US Myeloma Network (USMN) — a first-of-its-kind national clinical research network designed to accelerate the prevention ...

Experts highlight updated findings from CARTITUDE-2, how to mitigate late toxicities, and other key considerations in the modern multiple myeloma landscape.

A new study identifies UBA1 as a primary candidate biomarker for multiple myeloma by integrating ubiquitination and ...

During a live event, Robert Orlowski, MD, PhD, and participants discussed how access barriers, disease tempo, and bridging choices shape CAR T referral for a patient with early relapsed multiple ...

A risk-adapted treatment strategy with intensified induction, extended consolidation, and maintenance therapy is associated ...

A phase 1 clinical trial found that an investigational CAR-T therapy can lead to deep and durable responses in people with relapsed or refractory multiple myeloma.

Matthew J. Frigault, MD, and Adam D. Cohen, MD, outline how updated NCCN guidelines position CAR T-cell therapy in early ...

A phase 2 trial found that ultra-low-dose radiation therapy delivered in one or two sessions relieved painful bone lesions in ...

Metastatic multiple myeloma is a form of cancer of the bone marrow that has spread to other parts of the body. Common sites of metastasis include the skin, muscles, and lymph nodes. Multiple myeloma ...

*Oya Gilbert is bringing his “Mic Check Myeloma” tour to Chicago. The free event lands at mHub on Saturday, Oct. 24, with ...

Black Americans are more likely to develop multiple myeloma and are often diagnosed at a younger age. The reasons are not fully understood but may involve biological and genetic factors. MGUS, a ...